BioGend Therapeutics Co., Ltd.

As of June 30, 2026, BioGend Therapeutics Co., Ltd. carries a market capitalization of 3.25B, placing it among publicly traded companies globally. Its enterprise value stands at 2.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioGend Therapeutics Co., Ltd.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, BioGend Therapeutics Co., Ltd. has 134.32M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, BioGend Therapeutics Co., Ltd. maintains a current ratio of 32.13, meaning it holds 32.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BioGend Therapeutics Co., Ltd. recorded an income tax benefit of -6.21M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, BioGend Therapeutics Co., Ltd.'s stock has declined approximately 47.91% over the past 52 weeks. The 50-day moving average sits at 25.33, while the 200-day moving average is 29.61.

As of June 30, 2026, BioGend Therapeutics Co., Ltd. holds 849.79M in cash and equivalents against 4.76M in total debt, resulting in a net debt position of -149.79M. Total book value stands at 1.07B, with working capital of 940.34M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

BioGend Therapeutics Co., Ltd.'s most recent stock split took place on January 28, 2026.